Literature DB >> 32030685

Translational Landscape of mTOR Signaling in Integrating Cues Between Cancer and Tumor Microenvironment.

Chiara Bazzichetto1, Fabiana Conciatori1, Italia Falcone1, Ludovica Ciuffreda2.   

Abstract

The mammalian target of rapamycin (mTOR) represents a critical hub for the regulation of different processes in both normal and tumor cells. Furthermore, it is now well established the role of mTOR in integrating and shaping different environmental paracrine and autocrine stimuli in tumor microenvironment (TME) constituents. Recently, further efforts have been employed to understand how the mTOR signal transduction mechanisms modulate the sensitivity and resistance to targeted therapies, also for its involvement of mTOR also in modulating angiogenesis and tumor immunity. Indeed, interest in mTOR targeting was increased to improve immune response against cancer and to develop new long-term efficacy strategies, as demonstrated by clinical success of mTOR and immune checkpoint inhibitor combinations. In this chapter, we will describe the role of mTOR in modulating TME elements and the implication in its targeting as a great promise in clinical trials.

Entities:  

Keywords:  Angiogenesis; Cancer; Combination therapy; Immunotherapy; TME; Targeted therapy; Tumor–stroma interactions; mTOR pathway; mTORC1; mTORC2

Mesh:

Substances:

Year:  2020        PMID: 32030685     DOI: 10.1007/978-3-030-35582-1_4

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  5 in total

1.  A Novel Signature Based on mTORC1 Pathway in Hepatocellular Carcinoma.

Authors:  Zhuomao Mo; Shuqiao Zhang; Shijun Zhang
Journal:  J Oncol       Date:  2020-09-15       Impact factor: 4.375

2.  Comprehensive Analysis of mTORC1 Signaling Pathway-Related Genes in the Prognosis of HNSCC and the Response to Chemotherapy and Immunotherapy.

Authors:  Zhao Ding; Hailong Shen; Ke Xu; Yu Wu; Shuhao Wang; Fangzheng Yi; Daming Wang; Yehai Liu
Journal:  Front Mol Biosci       Date:  2022-04-29

3.  Genomic signature of MTOR could be an immunogenicity marker in human colorectal cancer.

Authors:  Chenxing Wang; Batuer Aikemu; Yanfei Shao; Sen Zhang; Guang Yang; Hiju Hong; Ling Huang; Hongtao Jia; Xiao Yang; Minhua Zheng; Jing Sun; Jianwen Li
Journal:  BMC Cancer       Date:  2022-07-26       Impact factor: 4.638

Review 4.  Emerging role of mTOR in tumor immune contexture: Impact on chemokine-related immune cells migration.

Authors:  Jing Jin; Qijie Zhao
Journal:  Theranostics       Date:  2020-05-15       Impact factor: 11.556

Review 5.  Crosstalk of Hedgehog and mTORC1 Pathways.

Authors:  Lasse Jonsgaard Larsen; Lisbeth Birk Møller
Journal:  Cells       Date:  2020-10-18       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.